Inclusion of the PD-L1 blocker was designed to counteract the inhibitory effect of PD-1/PD-L1 interaction on CD8+ T cells and NK cells, leading to greatly enhanced anti-tumor immunity (reviewed in [21]). Here, CD8A is linked to neoplasm.